Senolytics to Improve Osteoporosis Therapy

NCT06018467 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Osteopenia, Osteoporosis
Age-related Bone Loss

Interventions

DRUG: Dasatinib 100 Mg Oral Tablet
DIETARY_SUPPLEMENT: Quercetin 1.250 mg (oral)
DIETARY_SUPPLEMENT: Nicotinamide Riboside 1g (oral)

Sponsor

Odense University Hospital

Collaborators

[object Object]
[object Object]